Brexit Could Make UK A 'Second-Tier State' For Innovative New Drugs, Business Committee Warns
Executive Summary
A report from the UK House of Commons business committee on its inquiry into the impact of Brexit on the pharma sector has flagged up the multiple challenges facing companies and regulators.